or
forgot password

Phase I Study To Determine The Maximally Tolerated Dose Of Oral, Daily CP-868,596 And CP-868,596 Plus AG-013736 When Given In Combination With Docetaxel Administered Every 3 Weeks To Patients With Advanced Solid Tumors


Phase 1
18 Years
N/A
Not Enrolling
Both
Advanced Solid Tumors

Thank you

Trial Information

Phase I Study To Determine The Maximally Tolerated Dose Of Oral, Daily CP-868,596 And CP-868,596 Plus AG-013736 When Given In Combination With Docetaxel Administered Every 3 Weeks To Patients With Advanced Solid Tumors


Inclusion Criteria:



- Be ≥18 years old and with histologically or cytologically confirmed advanced solid
tumors refractory/resistant to currently available therapies or for which there is no
standard therapy.

- Patients with primary brain tumors are not eligible.

- Have at least one site of measurable disease.

Exclusion Criteria:

- Received chemotherapy (including targeted agents such as erlotinib), radiotherapy,
immunotherapy or any investigational therapy within 3 weeks of study entry (within 6
weeks for previous treatments with nitrosoureas or mitomycin C).

- Received tamoxifen within 4 weeks prior to study entry.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

First-cycle Dose Limiting Toxicities

Outcome Time Frame:

2.5 years

Safety Issue:

Yes

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A5301005

NCT ID:

NCT00949624

Start Date:

December 2005

Completion Date:

June 2008

Related Keywords:

  • Advanced Solid Tumors
  • PDGFr Inhibition;
  • VEGFr inhibition;
  • targeted therapy
  • Neoplasms

Name

Location
Pfizer Investigational Site Asheville, North Carolina  28801